{
    "root": "17b869c0-6c85-4436-a3f1-2b411c2f3367",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Metformin Hydrochloride",
    "value": "20250310",
    "ingredients": [
        {
            "name": "METFORMIN HYDROCHLORIDE",
            "code": "786Z46389E"
        },
        {
            "name": "Copovidone K25-31",
            "code": "D9C330MD8B"
        },
        {
            "name": "carboxymethylcellulose sodium, unspecified form",
            "code": "K679OBS311"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "magnesium stearate",
            "code": "70097M6I30"
        }
    ],
    "indications": "Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
    "contraindications": "Adult Dosage for Metformin Hydrochloride Extended-Release Tablets: Swallow metformin hydrochloride extended-release tablets whole and never crush, cut or chew ( 2.1 ) Starting dose: 500 mg orally once daily with the evening meal ( 2.1 ) Increase the dose in increments of 500 mg weekly, up to a maximum of 2,000 mg once daily with the evening meal ( 2.1 ) Patients receiving metformin hydrochloride tablets may be switched to metformin hydrochloride extended-release tablets once daily at the same total daily dose, up to 2,000 mg once daily ( 2.1 ) Renal Impairment: Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.3 ) Do not use in patients with eGFR below 30 mL/minute/1.73 m 2 ( 2.3 ) Initiation is not recommended in patients with eGFR between 30 mL/minute/1.73 m 2 and 45 mL/ minute/1.73 m 2 ( 2.3 ) Assess risk/benefit of continuing if eGFR falls below 45 mL/minute/1.73 m 2 ( 2.3 ) Discontinue if eGFR falls below 30 mL/minute/1.73 m 2 ( 2.3 ) Discontinuation for Iodinated Contrast Imaging Procedures: Metformin hydrochloride extended-release tablets may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures ( 2.4 )",
    "warningsAndPrecautions": "16.1 How Supplied\n                  \n                  \n                     Metformin hydrochloride extended-release tablets USP, 500 mg are oval white tablets, with \"OE\" debossed on one side and \"584\"\n                  debossed on the other side.\n                  \n                     Product: 71335-0720\n                  \n                  \n                     NDC 71335-0720-1: 60 TABLET in a BOTTLE\n                     NDC 71335-0720-2: 30 TABLET in a BOTTLE\n                     NDC 71335-0720-3: 100 TABLET in a BOTTLE\n                     NDC 71335-0720-4: 90 TABLET in a BOTTLE\n                     NDC71335-0720-5 : 120 TABLET in a BOTTLE\n                     NDC 71335-0720-6: 15 TABLET in a BOTTLE\n                     NDC 71335-0720-7: 45 TABLET in a BOTTLE\n                     NDC 71335-0720-8: 180 TABLET in a BOTTLE\n                     NDC 71335-0720-9: 20 TABLET in a BOTTLE\n                  \n                  \n                     Metformin hydrochloride extended-release tablets USP, 750 mg are white, capsule shaped tablets, with \"OE\" debossed on one side and\n                  \"585\" debossed on the other side.\n                  \n                     Product: 71335-0776\n                  \n                  \n                     NDC 71335-0776-1: 30 TABLET in a BOTTLE\n                     NDC 71335-0776-2: 90 TABLET in a BOTTLE\n                     NDC 71335-0776-3: 60 TABLET in a BOTTLE\n                     NDC 71335-0776-4: 180 TABLET in a BOTTLE\n                     NDC 71335-0776-5: 100 TABLET in a BOTTLE\n                  \n                  \n                     16.2 Storage\n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted from 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.]\n                  Dispense in light-resistant containers.\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions": "Metformin hydrochloride extended-release tablets are contraindicated in patients with:\n                  \n                     Severe renal impairment (eGFR below 30 mL/min/1.73 m2) [see Warnings and Precautions (5.1)].\n                     Hypersensitivity to metformin.\n                     Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma."
}